The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Current practices in 1st- (1L), 2nd- (2L), and 3rd-line (3L) treatment for metastatic colorectal cancer (mCRC).
Stephen F Thompson
Employment or Leadership Position - Sanofi
Sheikh Usman Iqbal
Employment or Leadership Position - Sanofi
Sarah Naoshy
Consultant or Advisory Role - Sanofi
Daniel B Ng
Employment or Leadership Position - Sanofi
Michael L Andria
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Steven A Sherman
Consultant or Advisory Role - Analytica LA-SER International
Elisabetta Malangone
Employment or Leadership Position - Analytica LA-SER International
Consultant or Advisory Role - Analytica LA-SER International
Research Funding - Sanofi
Lee Stern
Research Funding - Sanofi
Magdaliz Gorritz-Kindu
Employment or Leadership Position - Analytica International
Consultant or Advisory Role - Analytica International
Research Funding - Sanofi